Argos Therapeutics Inc. (NASDAQ:ARGS) saw unusually-strong trading volume on Thursday . Approximately 921,330 shares traded hands during trading, an increase of 397% from the previous session’s volume of 185,206 shares.The stock last traded at $5.33 and had previously closed at $6.46.

ARGS has been the topic of several analyst reports. Piper Jaffray Cos. restated an “overweight” rating and set a $11.00 price objective on shares of Argos Therapeutics in a report on Monday, June 20th. Needham & Company LLC restated a “buy” rating and set a $11.00 price objective on shares of Argos Therapeutics in a report on Friday, June 17th. Zacks Investment Research upgraded Argos Therapeutics from a “hold” rating to a “buy” rating and set a $6.75 price objective on the stock in a report on Tuesday, May 17th. Roth Capital raised their price objective on Argos Therapeutics from $11.00 to $18.00 and gave the stock a “buy” rating in a report on Tuesday, April 19th. Finally, FBR & Co restated a “buy” rating on shares of Argos Therapeutics in a report on Tuesday, June 14th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $11.84.

The stock’s market cap is $136.19 million. The firm’s 50-day moving average price is $6.00 and its 200 day moving average price is $5.63.

Argos Therapeutics (NASDAQ:ARGS) last announced its earnings results on Thursday, May 12th. The biopharmaceutical company reported ($0.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by $0.01. On average, equities analysts forecast that Argos Therapeutics Inc. will post ($1.74) EPS for the current fiscal year.

Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.